Measurement of chemotherapy-induced alopecia—time to change

Hurk, Corina van den; Winstanley, Julie; Young, Annie; Boyle, F.

doi:10.1007/s00520-015-2647-3

Cited by 16 publications

(6 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similar results were reported up to 12 years after the end of treatment in women with ovarian cancer who received chemotherapy [13]. The side effect that is most neglected is alopecia [14]. It is not life threatening, temporary and 'only' cosmetic.…”

supporting

confidence: 75%

Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria

Beijers

Mols²,

Hurk

et al. 2015

Acta Oncologica

View full text Add to dashboard Cite

supporting

confidence: 75%

Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria

Beijers

Mols²,

Hurk

et al. 2015

Acta Oncologica

View full text Add to dashboard Cite

“…The primary end point was based on patient self-assessment, a relevant method for determining relative usefulness or worth of the device to patients themselves. 3,29–32 Age- and chemotherapy treatment–matched controls were enrolled to demonstrate that the chemotherapy regimens in this study caused severe hair loss.…”

Section: Discussionmentioning

confidence: 99%

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Rugo

Klein

Melin

et al. 2017

JAMA

142

103

View full text Add to dashboard Cite

IMPORTANCE Chemotherapy-induced alopecia is a common and distressing adverse effect. In previous studies of scalp cooling to prevent chemotherapy-induced alopecia, conclusions have been limited.OBJECTIVES To evaluate whether use of a scalp cooling system is associated with a lower amount of hair loss among women receiving specific chemotherapy regimens for early-stage breast cancer and to assess related changes in quality of life. DESIGN, SETTING, AND PARTICIPANTSA prospective cohort study conducted at 5 US medical centers of women with stage I or II breast cancer receiving adjuvant or neoadjuvant chemotherapy regimens excluding sequential or combination anthracycline and taxane (106 patients in the scalp cooling group and 16 in the control group; 14 matched by both age and chemotherapy regimen). The study was conducted between August 2013 and October 2014 with ongoing annual follow-up for 5 years.EXPOSURES Use of a scalp cooling system. Scalp cooling was initiated 30 minutes prior to each chemotherapy cycle, with scalp temperature maintained at 3°C (37°F) throughout chemotherapy and for 90 minutes to 120 minutes afterward.MAIN OUTCOMES AND MEASURES Self-estimated hair loss using the Dean scale was assessed 4 weeks after the last dose of chemotherapy by unblinded patient review of 5 photographs. A Dean scale score of 0 to 2 (Յ50% hair loss) was defined as treatment success. A positive association between scalp cooling and reduced risk of hair loss would be demonstrated if 50% or more of patients in the scalp cooling group achieved treatment success, with the lower bound of the 95% CI greater than 40% of the success proportion. Quality of life was assessed at baseline, at the start of the last chemotherapy cycle, and 1 month later. Median follow-up was 29.5 months. RESULTS Among the 122 patients in the study, the mean age was 53 years (range, 28-77 years); 77.0% were white, 9.0% were black, and 10.7% were Asian; and the mean duration of chemotherapy was 2.3 months (median, 2.1 months). No participants in the scalp cooling group received anthracyclines. Hair loss of 50% or less (Dean score of 0-2) was seen in 67 of 101 patients (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0%) in the control group (P < .001). Three of 5 quality-of-life measures were significantly better 1 month after the end of chemotherapy in the scalp cooling group. Of patients who underwent scalp cooling, 27.3% (95% CI, 18.0%-36.6%) reported feeling less physically attractive compared with 56.3% (95% CI, 31.9%-80.6%) of patients in the control group (P = .02). Of the 106 patients in the scalp cooling group, 4 (3.8%) experienced the adverse event of mild headache and 3 (2.8%) discontinued scalp cooling due to feeling cold.CONCLUSIONS AND RELEVANCE Among women undergoing non-anthracycline-based adjuvant chemotherapy for early-stage breast cancer, the use of scalp cooling vs no scalp cooling was associated with less hair loss at 4 weeks after the last dose of chemotherapy. Further research is ne...

show abstract

“…CIA affects various aspects of cancer patient's quality of life [41] and frequently ranked among top distressing/troublesome side effects of chemotherapy especially in female breast cancer patients [42,43] to the extent of refusal to chemotherapy [42,44]. The need to improve the management and measurement of CIA is emphasized in recent literature [45]. In the present study, the impact of TAPP-CZ supplementation on CIA using the modern, quantitative and precise technique (TrichoScan ® ) to measure hair density, and % hairs in anagen (growth) and telogen (fall) phases of patients as a measure of alopecia were evaluated.…”

Section: Discussionmentioning

confidence: 99%

Efficacy and Safety of Standardized Cinnamon Bark Extract for the Prevention of Chemotherapy-Induced Weight Loss and Alopecia in Patients With Breast Cancer: A Randomized, Double-Blind, and Placebo-Controlled Study

Mehta

Thakurdesai

2019

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: The objective of the study was to evaluate the effects of IND02 (standardized Cinnamon bark extract) supplementation for the prevention of side effects of cancer chemotherapy in female patients with breast cancer. Methods: The study was conducted using double-blind, placebo-controlled design in 34 female breast cancer patients during the first 4 consecutive 21-day cycles of the standard chemotherapy regimen. The active treatment (IND02 capsules, 400 mg, one capsule, and thrice a day) or matching placebo was orally administrated in randomized (1:1 ratio) patients. The efficacy outcome measures were reduction in chemotherapy-induced weight loss, alopecia (hair fall), and other side effects. The safety outcome measures were hematology, ECG, vital signs, adverse event monitoring, and laboratory safety measurements. Results: The patients on the treatment with IND02 had shown significant protection from chemotherapy-induced severe weight loss (cachexia) and alopecia (reduced hair density and % hairs in the anagen phase, and increased % hairs in telogen phase) which was seen in the placebo group. IND02 treatment was found safe and well-tolerated during the study. Conclusion: Concomitant use of IND02 in breast cancer patients during breast cancer chemotherapy showed a clinical promise regarding efficacy and safety in preventing chemotherapy-induced weight loss and alopecia.

show abstract

Measurement of chemotherapy-induced alopecia—time to change

Cited by 16 publications

References 14 publications

Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria

Are chemotherapy-associated symptoms underestimated? A view beyond common toxicity criteria

Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer

Efficacy and Safety of Standardized Cinnamon Bark Extract for the Prevention of Chemotherapy-Induced Weight Loss and Alopecia in Patients With Breast Cancer: A Randomized, Double-Blind, and Placebo-Controlled Study

Contact Info

Product

Resources

About